Treatment of such diseases in adults as: – cryptococcal meningitis; the coccidioidomycosis; – invasive candidiasis; – candidiasis of the mucous membranes, including oropharyngeal candidiasis and esophageal candidiasis, candiduria, chronic candidiasis of the skin and mucous membranes; – chronic atrophic candidiasis (candidiasis caused by the use of dentures) with the inefficiency of local dental hygiene products; – vaginal candidiasis, acute or recurrent, when local therapy is not appropriate; – Candida balanitis when local therapy is not appropriate; – dermatomycosis, including mycosis of the feet, mycosis of smooth skin, inguinal dermatomycosis, multi-colored lichen and Candida infections of the skin, when indicated to use systemic therapy; – dermatophytic onychomycosis, when the use of other drugs is not advisable.
Fluconazol 100 mg Composition:
active substance: Fluconazole 1 tablet contains fluconazole 100 mg
auxiliary substances: lactose monohydrate, potato starch, povidone, anhydrous colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E 171), talc, polyethylene glycol 6000 (macrogol 6000), polysorbate
Fluconazol 100 mg Dosage form
Fluconazol 100 mg Pharmacotherapeutic group
Antifungal agents for systemic use. Triazole derivatives. ATC code J02A C01.
Treatment of diseases in adults such as:
mucosal candidiasis, including oropharyngeal candidiasis, esophageal candidiasis, candiduria, chronic skin and mucosal candidiasis
chronic atrophic candidiasis (candidiasis caused by the use of dentures) with ineffective local dental hygiene products
candidal balanitis when local therapy is not appropriate
dermatomycosis, including mycosis of the feet, mycosis of smooth skin, inguinal ringworm, tinea versicolor and candidal skin infections when systemic therapy is not appropriate
dermatophytic onychomycosis, when the use of other drugs is not appropriate.
Prevention of such diseases in adults as:
relapse of cryptococcal meningitis in patients at high risk of developing it
recurrence of oropharyngeal or esophageal candidiasis in patients with HIV at high risk of developing it
a decrease in the frequency of relapses of vaginal candidiasis (4 or more cases per year)
prevention of candidal infections in patients with long-term neutropenia (for example, patients with malignant blood diseases receiving chemotherapy or patients with hematopoietic stem cell transplantation).
It is usually possible to use the drug at the age of 5 years.
Fluconazole is used in children for the treatment of mucosal candidiasis (oropharyngeal candidiasis, esophageal candidiasis), invasive candidiasis, cryptococcal meningitis, and for the prevention of candidal infections in immunocompromised patients. The drug can be used as supportive therapy to prevent recurrence of cryptococcal meningitis in children at high risk of developing it.
Drug therapy can be started before the results of culture and other laboratory tests are obtained; after receiving the results, antibiotic therapy should be adjusted accordingly.
Hypersensitivity to fluconazole, other azole compounds or to any auxiliary substance of the drug.
Concomitant use of fluconazole and terfenadine in patients who use fluconazole multiple times at doses of 400 mg / day or more (according to the results of a multiple-use interaction study).
Concomitant use of fluconazole and other drugs that prolong the QT interval and are metabolized by the CYP3A4 enzyme (for example, cisapride, astemizole, pimozide, quinidine and erythromycin).